(CNN)U.S. Food and Drug Administration Tuesday issued Emergency Use Authorization to allow healthcare providers to change how they use Gynneos Did. Monkeypox vaccine is administered and supplies are expanded amid high demand.
Vaccines can now be administered intradermally, or between the layers of the skin, in high-risk adults, rather than subcutaneously or under the skin, which was previously abandoned. This allows a healthcare provider to get her 5 doses out of her standard single-dose vial.
The new EUA also allows subcutaneous vaccination for those under the age of 18 who are at high risk of infection.
The move comes a week after the Biden administration declared monkeypox a public health emergency. It was done shortly after. This has given the FDA and other government health agencies more flexibility in dealing with the spread of the virus.
Earlier Tuesday, U.S. Department of Health and Human Services Commissioner Xavier Becerra made a decision that paved the way for the FDA's move.
As of Monday, the US government has shipped 617,693 doses of Jynneos to states and jurisdictions. The US Centers for Disease Control and Prevention estimates that at least 1.5 million people in the United States are eligible for monkeypox vaccination.
Intradermal vaccination "essentially stays in the skin. It doesn't go through the skin," says Dr. Danielle Griffin, an infectious disease expert at Columbia University.
"There are special cells in the skin that are very good at helping vaccines stimulate the body's immune system," he writes. These cells, called cells, are excellent at generating an immune response, Griffin said.
"They live in the skin and are good at teaching the immune system what it needs to respond to," he said. If you can give it intradermally, you can do it in lower doses...they just need to prove they get the same immune response," he said.